Biomarkers of METAP2 inhibitors and applications thereof
US11612577B2 · kind B2 · utility
1Cited by
40References
14Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 28, 2019 |
| Grant date | Mar 28, 2023 |
| Priority date | — |
| Expiry date | Jun 14, 2040 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P3/10
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure relates to small molecule or polymer conjugated MetAP2 inhibitors. The present disclosure also relates to methods of treating, or ameliorating at least one symptom of metabolic dysfunction associated with a treatment in a subject having a disease, such as cancer. The present disclosure also relates to methods of treating, or ameliorating at least one symptom of cancer comprising administering a combination of a polymer conjugated MetAP2 inhibitors and at least one second agent wherein the second agent may induce metabolic dysfunction.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.